Day 1 | Day 2 | Day 3
Final Agenda
Monday, May 2
1:00-2:00 Main Conference Registration
2:00-2:10 Welcoming Remarks from Conference Director
Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute
2:10-2:15 Chairperson’s Opening Remarks
Nicholas C. Dracopoli, Ph.D., Vice President, Centocor R&D, Johnson & Johnson
2:15-2:45 Can Biomarkers Explain Why Drugs Fail? The Impact of Measuring Target Engagement, Downstream Effects and Preselecting Patients on Meeting Clinical Endpoints
Nicholas C. Dracopoli, Ph.D., Vice President, Centocor R&D, Johnson & Johnson
2:45-3:15 How Biomarkers Can Improve Clinical Drug Development and Drug Approval
Pravin Jadhav, Ph.D., FCP, Team Leader, Division of Pharmacometrics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
3:15-3:45 Applied Biomarkers: Where We Need More Research and Where We Don’t
Felix W. Frueh, Ph.D., President, Medco Research Institute, Medco Health Solutions, Inc.
3:45-4:15 The Yin and Yang of Biomarkers
Stefan Scherer, M.D., Ph.D., Global Biomarker Head, Product Development Oncology, Genentech
Personalized healthcare (PHC) is built on the premise that laboratory tests can accurately predict the response of individual patients to a particular treatment. The recent stakeholder behaviors, from regulators to payers and patients, physicians and pharmaceutical and diagnostic industry, suggest that the pursuit of therapeutic stratification will become a standard in oncology drug development. Among the growing number of examples for individualization of cancer therapy, Avastin and Herceptin will be presented as case studies for translation of results from pre-clinical research into a successful targeted therapy in a selected patient population and to demonstrate the associated challenges.
4:15-5:15 Opening Reception in the Exhibit Hall with Poster Viewing
Day 1 | Day 2 | Day 3